Liposomal Bupivacaine and Transoral Robotic Surgery

Geisinger Clinic80 enrolled

Overview

This study is for patients with oropharyngeal squamous cell carcinoma. We want to learn more about how we can optimize pain control in patients who undergo transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma. Our goal is to determine if a local anesthetic called EXPAREL® (Liposomal Bupivacaine) impacts postsurgical pain and swallow function in patients with oropharyngeal squamous cell carcinoma undergoing TORS. EXPAREL® is an FDA-approved anesthetic drug that provides long-lasting and precise pain relief when injected into the surgical wound. Our study team wants to determine if injecting EXPAREL® into the surgical wound will provide better pain relief and swallow function when compared to patients who do not undergo postoperative EXPAREL® injection. Both options for postoperative pain control are considered standard of care for patients undergoing TORS.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Oropharyngeal Cancer Dysphagia, Oropharyngeal Post Operative Pain Transoral Robotic Surgery

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, greater than or equal to 18 years of age; Patients of all genders; Patients undergoing transoral robotic surgery; Patient who are able and willing to give consent Exclusion Criteria: * Patients with an allergy to Bupivacaine or other amide anesthetics; Patients with a carnitine deficiency

Outcomes

Primary Outcomes

Postoperative Pain Control

We will be measuring subjects' postoperative maximum visual analog pain scores on each postoperative day. Scale: 0-10, 0 represents no pain and 10 represents the worst pain

Time frame: 3 months

Postoperative Dysphagia with Endoscopic Swallow Study

Patients will undergo a functional endoscopic swallow study with a speech language pathologist during their first postoperative visit.

Time frame: 3 months

Postoperative Dysphagia with Dysphagia Survey

Patients will undergo an evaluation of their swallow function via the MD Anderson Dysphagia Inventory survey with a speech language pathologist during their first postoperative visit.

Time frame: 3 months

Secondary Outcomes

Postoperative Pain Medication Usage

We will be measuring the doses of pain medication that patients requiring during their postoperative course.

Time frame: 3 months

Liposomal Bupivacaine and Transoral Robotic Surgery

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts